Weight loss program for overweight patients with type 2 diabetes
Official title: eHealth Diabetes Remission Trial (Swedish: Remission av Typ 2 Diabetes Med hjälp av eHälsa
Run by Umeå University · NCT05491005 · Data updated 2026-11-12
This study is testing a weight loss program for overweight people with type 2 diabetes to see if a strict diet and different types of support can help them lose weight and possibly improve their diabetes over two years.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 20 Years to 70 Years |
| Sex | All |
| Enrollment | 106 (estimated) |
| Sponsor | Umeå University Academic / other |
| Locations | 3 sites (Jönköping and 2 other locations) |
| Status | Recruiting |
| Started | August 31, 2022 |
| Main results expected | January 31, 2028 |
| Study ends | January 31, 2028 |
| Registry record updated | April 30, 2026 |
| Trial ID | NCT05491005 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are overweight individuals with type 2 diabetes diagnosed within the last six years and a BMI of 27 kg/m2 or higher.
✕Probably not a fit
Patients currently on insulin treatment or with severe health conditions such as recent myocardial infarction or severe heart failure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial involves overweight patients with type 2 diabetes who undergo a total diet replacement of 850 kcal/day for three months, aiming for a weight loss of 15 kg and potential diabetes remission. Participants are randomized into two groups: one receiving eHealth follow-up and the other receiving face-to-face follow-up, although both groups receive the same dietary advice. After the initial three months, food is gradually reintroduced, and a tailored energy prescription is provided to prevent weight regain. The total duration of the study is two years, with ongoing support through cognitive behavioral therapy to help maintain weight loss.
Why it matters
Potential benefit: If successful, this program could lead to significant weight loss and remission of type 2 diabetes for participants.
How similar studies have gone: Other studies have shown promising results with similar dietary interventions for diabetes remission, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 2 diabetes with duration 0-6 years * BMI 27 kg/m2 and higher * HbA1c 43 mmol/mol or higher (48 or higher if without diabetes medication) Exclusion Criteria: * Insulin treatment * Weight loss more than 5 kg during the past 6 months * Diagnosed eating disorder * eGFR \< 30 ml/min/1,73m2 * Myocardial infarction last six months * Severe heart failure (NYHA class III) * Ongoing cancer * Pregnancy * Treatment with antipsychotic drugs
Where it's running
-
Bra Liv Råslätt vårdcentral
Jönköping, Sweden Recruiting -
Department of Public Health and Clinical Medicine, Medicine
Umeå, Sweden Recruiting -
Örnsköldsvik hospital
Örnsköldsvik, Sweden Not yet recruiting
Study contacts
- Principal investigator: Julia Otten, PhD — Umeå University
- Study coordinator: Julia Otten, PhD
- Email: julia.otten@umu.se
- Phone: +46703341559
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Proliverenol for liver fat and insulin resistance in type 2 diabetes
This study tests whether adding Proliverenol to standard diabetes care can improve liver fat and blood sugar control in adults with type 2 diabetes.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Safety test of NNC9836-0001 in adults with overweight/obesity or type 2 diabetes
This study tests whether the new medicine NNC9836-0001 is safe and tolerable in adults who are overweight or have type 2 diabetes, compared to placebo.
-
RIGHTEST iFree 2 CGM in Pregnant Women With Diabetes
This study tests the accuracy and safety of the RIGHTEST iFree 2 continuous glucose monitor in pregnant adults with type 1, type 2, or gestational diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Maridebart cafraglutide vs. semaglutide for type 2 diabetes on metformin
This trial tests whether maridebart cafraglutlide is as good as semaglutide at improving blood sugar in adults with type 2 diabetes who take metformin (with or without an SGLT-2 inhibitor).
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.